Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F16%3A00464251" target="_blank" >RIV/61388971:_____/16:00464251 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11140/16:10326040 RIV/00669806:_____/16:10326040
Result on the web
<a href="http://dx.doi.org/10.21873/anticanres.11037" target="_blank" >http://dx.doi.org/10.21873/anticanres.11037</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.11037" target="_blank" >10.21873/anticanres.11037</a>
Alternative languages
Result language
angličtina
Original language name
Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer
Original language description
Background/Aim: Current research of prostate cancer (PCa) offers a promising way of identifying patients with adverse prognosis who do benefit from radical treatment that can affect quality of life as resections are associated with numerous side-effects. The aim of our study was to evaluate the relationship of TMPRSS2-ERG fusion gene status, tumor tissue prostate-specific antigen (PSA), prostate cancer antigen 3 (PCA3), miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy. Patients and Methods: The study group consisted of 108 patients who underwent radical prostatectomy. PSA was measured in peripheral blood collected preoperativelly. The expression of TMPRSS2-ERG transcript and the expression of miR-23b, miR-26a and miR-221 in formalin-fixed, paraffin-embedded (FFPE) tumor tissues was analyzed by reverse transcription (RT) real-time polymerase chain reaction (PCR).
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Anticancer Research
ISSN
0250-7005
e-ISSN
—
Volume of the periodical
36
Issue of the periodical within the volume
7
Country of publishing house
GR - GREECE
Number of pages
7
Pages from-to
4787-4793
UT code for WoS article
000384001800057
EID of the result in the Scopus database
2-s2.0-84991728589